Amplyx Pharmaceuticals develops products for life-threatening infections, including deadly fungal pathogens, and today annouced that the FDA has granted a fourth Qualified Infectious Disease Product (QIDP) designation to APX001, the company’s lead antifungal product candidate. The QIDP designation, a provision under the U.S. Generating Antibiotic Incentives Now (GAIN) Act, was approved by Congress in 2012 to…